Chia Tai Tianqing Pharmaceutical Group

Subsidiary of Sino Biopharmaceutical (1177) · China

Assets

(3 total)
3Total Assets
1Approved
1Phase 3 / Filed
1Phase 1–2 / Early
6Diseases
Quick filter:
Showing 3 of 3 assets
Target & Modality
Approved
PD-1Monoclonal antibody
Non-Small Cell Lung CancerHepatocellular CarcinomaNasopharyngeal Carcinoma
Phase 3
Peroxisome proliferator-activated receptors (PPARs) · PPAR (pan-agonist)Small molecule
Type 2 DiabetesMASH / NASH
Phase 2
TSLPMonoclonal antibody
Atopic Dermatitis

Upcoming events

No upcoming trial completions or earnings dates on record for this company's assets.

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

16 November 2026Topline resultBosakitugPhase 2 ADMIRATION trial of bosakitug misses primary endpoint

Financial reports

No financial reports recorded.